190 related articles for article (PubMed ID: 31945264)
41. Cloning, high-level expression, single-step purification, and binding activity of His6-tagged recombinant type B botulinum neurotoxin heavy chain transmembrane and binding domain.
Zhou Y; Singh BR
Protein Expr Purif; 2004 Mar; 34(1):8-16. PubMed ID: 14766296
[TBL] [Abstract][Full Text] [Related]
42. Structural analysis of botulinum neurotoxin type G receptor binding .
Schmitt J; Karalewitz A; Benefield DA; Mushrush DJ; Pruitt RN; Spiller BW; Barbieri JT; Lacy DB
Biochemistry; 2010 Jun; 49(25):5200-5. PubMed ID: 20507178
[TBL] [Abstract][Full Text] [Related]
43. Structural and mutational analyses of the receptor binding domain of botulinum D/C mosaic neurotoxin: insight into the ganglioside binding mechanism.
Nuemket N; Tanaka Y; Tsukamoto K; Tsuji T; Nakamura K; Kozaki S; Yao M; Tanaka I
Biochem Biophys Res Commun; 2011 Jul; 411(2):433-9. PubMed ID: 21749855
[TBL] [Abstract][Full Text] [Related]
44. A Comprehensive Structural Analysis of
Gregory KS; Acharya KR
Toxins (Basel); 2023 Jan; 15(2):. PubMed ID: 36828407
[TBL] [Abstract][Full Text] [Related]
45. Characterization of the functional activity of botulinum neurotoxin subtype B6.
Kohda T; Nakamura K; Hosomi K; Torii Y; Kozaki S; Mukamoto M
Microbiol Immunol; 2017 Nov; 61(11):482-489. PubMed ID: 28898517
[TBL] [Abstract][Full Text] [Related]
46. Structural analysis of the receptor binding domain of botulinum neurotoxin serotype D.
Zhang Y; Buchko GW; Qin L; Robinson H; Varnum SM
Biochem Biophys Res Commun; 2010 Oct; 401(4):498-503. PubMed ID: 20858456
[TBL] [Abstract][Full Text] [Related]
47. Ganglioside GT1b as a complementary receptor component for Clostridium botulinum neurotoxins.
Kozaki S; Kamata Y; Watarai S; Nishiki T; Mochida S
Microb Pathog; 1998 Aug; 25(2):91-9. PubMed ID: 9712688
[TBL] [Abstract][Full Text] [Related]
48. Receptor binding enables botulinum neurotoxin B to sense low pH for translocation channel assembly.
Sun S; Suresh S; Liu H; Tepp WH; Johnson EA; Edwardson JM; Chapman ER
Cell Host Microbe; 2011 Sep; 10(3):237-47. PubMed ID: 21925111
[TBL] [Abstract][Full Text] [Related]
49. Crystallographic evidence for doxorubicin binding to the receptor-binding site in Clostridium botulinum neurotoxin B.
Eswaramoorthy S; Kumaran D; Swaminathan S
Acta Crystallogr D Biol Crystallogr; 2001 Nov; 57(Pt 11):1743-6. PubMed ID: 11679763
[TBL] [Abstract][Full Text] [Related]
50. Synaptotagmins I and II act as nerve cell receptors for botulinum neurotoxin G.
Rummel A; Karnath T; Henke T; Bigalke H; Binz T
J Biol Chem; 2004 Jul; 279(29):30865-70. PubMed ID: 15123599
[TBL] [Abstract][Full Text] [Related]
51. Binding of Clostridium botulinum type C and D neurotoxins to ganglioside and phospholipid. Novel insights into the receptor for clostridial neurotoxins.
Tsukamoto K; Kohda T; Mukamoto M; Takeuchi K; Ihara H; Saito M; Kozaki S
J Biol Chem; 2005 Oct; 280(42):35164-71. PubMed ID: 16115873
[TBL] [Abstract][Full Text] [Related]
52. Preliminary X-ray crystallographic study of the receptor-binding domain of the D/C mosaic neurotoxin from Clostridium botulinum.
Nuemket N; Tanaka Y; Tsukamoto K; Tsuji T; Nakamura K; Kozaki S; Yao M; Tanaka I
Acta Crystallogr Sect F Struct Biol Cryst Commun; 2010 May; 66(Pt 5):608-10. PubMed ID: 20445271
[TBL] [Abstract][Full Text] [Related]
53. Identification of a unique ganglioside binding loop within botulinum neurotoxins C and D-SA .
Karalewitz AP; Kroken AR; Fu Z; Baldwin MR; Kim JJ; Barbieri JT
Biochemistry; 2010 Sep; 49(37):8117-26. PubMed ID: 20731382
[TBL] [Abstract][Full Text] [Related]
54. Domain organization in Clostridium botulinum neurotoxin type E is unique: its implication in faster translocation.
Kumaran D; Eswaramoorthy S; Furey W; Navaza J; Sax M; Swaminathan S
J Mol Biol; 2009 Feb; 386(1):233-45. PubMed ID: 19118561
[TBL] [Abstract][Full Text] [Related]
55. Botulinum neurotoxin subtype A2 enters neuronal cells faster than subtype A1.
Pier CL; Chen C; Tepp WH; Lin G; Janda KD; Barbieri JT; Pellett S; Johnson EA
FEBS Lett; 2011 Jan; 585(1):199-206. PubMed ID: 21126520
[TBL] [Abstract][Full Text] [Related]
56. Structural Analysis of Botulinum Neurotoxins Type B and E by Cryo-EM.
Košenina S; Martínez-Carranza M; Davies JR; Masuyer G; Stenmark P
Toxins (Basel); 2021 Dec; 14(1):. PubMed ID: 35050991
[TBL] [Abstract][Full Text] [Related]
57. Cocrystal structure of synaptobrevin-II bound to botulinum neurotoxin type B at 2.0 A resolution.
Hanson MA; Stevens RC
Nat Struct Biol; 2000 Aug; 7(8):687-92. PubMed ID: 10932255
[TBL] [Abstract][Full Text] [Related]
58. The receptor binding domain of botulinum neurotoxin serotype C binds phosphoinositides.
Zhang Y; Varnum SM
Biochimie; 2012 Mar; 94(3):920-3. PubMed ID: 22120109
[TBL] [Abstract][Full Text] [Related]
59. Crystal Structure of Botulinum Neurotoxin A2 in Complex with the Human Protein Receptor SV2C Reveals Plasticity in Receptor Binding.
Gustafsson R; Zhang S; Masuyer G; Dong M; Stenmark P
Toxins (Basel); 2018 Apr; 10(4):. PubMed ID: 29649119
[TBL] [Abstract][Full Text] [Related]
60. Botulinum neurotoxin D uses synaptic vesicle protein SV2 and gangliosides as receptors.
Peng L; Tepp WH; Johnson EA; Dong M
PLoS Pathog; 2011 Mar; 7(3):e1002008. PubMed ID: 21483489
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
